OKYO Pharma ’s Post

#ACC24 Spotlight: Data from the IMPROVE-HCM trial, presented by Martin S. Maron, MD, of Lahey Hospital & Medical Center, offer hope for patients with nonobstructive HCM, as results of the phase 2 trial suggest use of ninerafaxstat, a cardiac mitotrope from Imbria Pharmaceuticals, was well-tolerated and improved exercise capacity among patients with nonobstructive hypertrophic cardiomyopathy. Check out our coverage here: https://lnkd.in/eJfG2y6q #Cardiomyopathy #Cardiology

#DRYEYE a three headed monster? Nicholas Bruns, OD, FAAO discusses some of the new ocular surface treatment options and discusses his approach to treating dry eye for his patients. The bottom line: there are many tools to choose from and no two patients are alike. Take a listen as Dr. Bruns gives a high level overview on some of the drops availble to treat ocular surface disease. Financial Disclosures: RxSight, Staar Surgical, Bausch and Lomb, LensAR Ref: CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022. MIEBO. [package insert.]. Laval, Canada: Bausch & Lomb, Inc; 2023. Restasis [package insert]. North Chicago, IL: Abbvie.; 2017. Vevye (cyclosporine ophthalmic solution) 0.1% [package insert]. Harrow IP, LLC; 2023. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020 #optometry #eyecare #ophthalmology #eyehealth #ocularsurfacedisease Summit Eye Care

You may remember some of the key themes we shared ahead of #ASCO24. Post-congress, our experts are reflecting back on those themes and summarizing the key insights and takeaways on these modalities from ASCO 2024. Read more & get in touch: https://lnkd.in/eHCmAX36 #CancerResearch #ADCs #RadioPharmaceuticals #Bispecifics

We are thrilled to announce that JEITO has led a €75M Series B financing round for NMD Pharma A/S, a Danish clinical-stage biotech company dedicated to developing innovative treatments for patients living with severe neuromuscular disorders. Following our initial investment in 2022, this second round of funding illustrates our steady support to growing and perfoming NMD Pharma A/S and its ambition to become a leading, global, clinical-stage company. The proceeds will be used to complete three Phase 2 clinical Proof of Concept studies with NMD670, the company's leading CIC-1 inhibitor, which has the potential to restore muscle function in a range of rare neuromuscular diseases, including myasthenia gravis, spinal muscular atrophy, and Charcot Marie Tooth. The funding will also contribute to grow its pipeline and support the expansion of NMD Pharma’s clinical and commercial operations in Denmark and in the US. We are very proud to stand alongside Thomas Holm Pedersen, the CEO, and his team as they embark on this new chapter, driven by their unwavering commitment to making a positive impact on patients. Read more 👉 https://lnkd.in/ev_3hjv8 #FasterForThePatient #privateequity #lifesciences #biopharma #healthcare #neuromusculardisease

Discounts for the Neuromodulation Summit 2024 expire this Friday! 📢 Check out the full event guide now: https://ter.li/rw1ht3 This exclusive conference is industry’s must-attend meeting to join the community of 80+ experts in neuromodulation to share crucial insights into: ✅ How the CDRH is accelerating patient access to innovation ✅ How to overcome regulatory and clinical challenges to receive funding ✅ How the adoption of invasive and non-invasive devices differs ✅ How to choose which submission type is the best first step Joined by the likes of FDA, LivaNova, Axonics, Inc., Cognito Therapeutics, Inc., Neuspera Medical Inc., ClearPoint Neuro, Inc. and many more - this is not one to miss! Save up to $400 on your pass and join them in Boston this June: https://ter.li/wummg3

Humacyte made significant strides in the second quarter of 2024 to further our mission to improve patient’s lives and transform the practice of medicine. Laura Niklason MD and PhD, founder and CEO of Humacyte and Dale Sander, Chief Financial Officer, Chief Corporate Development Officer, Treasurer shared our Q2 2024 results on August 13th, 2024. FDA Extends Review of ATEV™ BLA for Vascular Trauma: The FDA notified Humacyte that additional time is needed to complete the review of the Biologics License Application (BLA) for the acellular tissue engineered vessel (ATEV) in vascular trauma, a first-in-class product granted Priority Review. Humacyte remains confident in the approvability of ATEV. ATEV Shows Positive Patency Results in Phase 3 Hemodialysis Access Trial: Topline results from the V007 Phase 3 trial (N=242) demonstrated ATEV's positive functional patency at 6 and 12 months (co-primary endpoints; p=0.0071) and significantly longer hemodialysis duration over 12 months (p=0.0162) compared to autogenous fistula, the current standard of care. ATEV Receives 3rd RMAT Designation for Advanced PAD: The FDA granted ATEV its third Regenerative Medicine Advanced Therapy (RMAT) designation for treatment of advanced peripheral artery disease (PAD), recognizing its potential impact for patients facing amputation. Progress in CABG and BioVascular Pancreas Programs: Humacyte reported progress across its pipeline, including promising preclinical results for the BioVascular Pancreas in type 1 diabetes, and positive 6-month primate data on ATEV remodeling for coronary artery bypass grafts. We are proud of these milestones and look forward to sharing more at upcoming medical meetings. Thank you to our dedicated team and partners for making these advancements possible! View the full press release here: https://lnkd.in/eTYJcP6H The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. #Humacyte #BiotechInnovation #Biotech $HUMA

⭐ MARCH'S FDA ROUNDUP - APP13007 In a joint statement, Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. have announced that the FDA has approved clobetasol propionate ophthalmic suspension 0.05% (#APP13007), for treating postoperative inflammation and pain after #OcularSurgery.3 The announcement notes that #APP13007 is the first FDA-approved ophthalmic #ClobetasolPropionate as the first new #OphthalmicSteroid to reach the market in more than 15 years. “Two Phase 3 clinical trials demonstrated rapid and sustained clearance of inflammation and pain relief that was statistically and clinically superior to its matching placebo (P <.001),” according to the report. “This novel eyedrop enters a $1.3 billion dollar market for topical ophthalmic steroids and steroid combinations, driven by an estimated seven million ocular surgeries performed annually in the United States.”3 Read more➡️: https://brnw.ch/21wItGD #Ophthalmology #EyeHealth #EyeCare #Ophthalmologist #EyeResearch #EyeMedication #Healthcare #HCSM #OphthalmicSuspension #ClinicalTrials #ClobetasolPropionateOphthalmicSuspension

In this era of divisiveness, it is refreshing to have societies with interests and expertise in #radiopharmaceuticals therapy come together. #nucmed #radonc https://lnkd.in/em4UYN5V

Listen in from a PBM's perspective! Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, touches on the recent FDA approvals of the first MS biosimilar and the first tocilizumab biosimilar.

The fantastic journey between our portfolio company NMD Pharma A/S and JEITO enters a new chapter. We're delighted to lead a €75M Series B funding round in NMD Pharma, less than two years after our initial investment in the company. NMD Pharma A/S stands out among the high-quality players in the European ecosystem and exemplifies the type of biopharma we aim to help grow into a leading, global, late-stage clinical company. With this new funding round, JEITO is committed to supporting the company in its mission to bring transformational drugs to patients suffering from severe neuromuscular disorders, such as myasthenia gravis, spinal muscular atrophy, or Charcot-Marie-Tooth. #FasterForThePatient #PrivateEquity #Biopharma #Healthcare #NeuromuscularDisease https://lnkd.in/eu5NhhvY